Clinical Study Results
• 47.8% of participants who got anifrolumab were BICLA responders. This was 86 out of 180 participants.
• 31.5% of the participants who got the placebo were BICLA responders. This was 57 out of 182 participants.
The chart below shows the results.
Percentage of BICLA responders after 52 weeks
60
47.8%
50
40
31.5%
30
20
10
0
Anifrolumab Placebo